Healthcare | December 29, 2021
Crysta IVF launches centre in Mumbai
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
It will be marketed under the brand name Molunamax
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
Natco Pharma has received approval for Covid 19 drug molnupiravir capsules 200 mg. for Indian market, which will be sold under brand name Molnunat
DCGI approved the drug based on the review of clinical data
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
Subscribe To Our Newsletter & Stay Updated
